ABBV | tickerfilter.com

Fundamental analysis

50%

Profitability 62%

Dept financing 27%

Liquidity 16%

Performance 52%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

3.14%

1 Month

12.58%

3 Months

21.36%

6 Months

9.10%

1 Year

19.30%

2 Year

45.43%

Key data

Stock price

$214.29

P/E Ratio

72.72

DAY RANGE

$209.00 - $214.99

EPS

$2.40

52 WEEK RANGE

$153.58 - $215.66

52 WEEK CHANGE

$19.30

MARKET CAP

311.087 B

YIELD

3.52%

SHARES OUTSTANDING

1.766 B

DIVIDEND

$1.55

EX-DIVIDEND DATE

07-15-2024

NEXT EARNINGS DATE

N/A

BETA

0.06

PUBLIC FLOAT

AVERAGE 10 VOLUME

$7,186,991

AVERAGE 30 VOLUME

$5,755,925

Company detail

CEO: Richard A. Gonzalez
Region: US
Website: abbvie.com
Employees: 50,000
IPO year: 2013

Issue type: Common Stock
Market: NYSE
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism.

ABBV - AbbVie Inc.